{"title": "PDF", "author": "PDF", "url": "https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/infant-mortality/meetings/10-covid-19-vaccination-pregnancy-delman.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "1 Centers for Disease Control and Prevention COVID- 19 Vaccination During Pregnancy: ACIP Recommendations and Safety Monitoring Dana Meaney -Delman, MD MPH Chief, Infant Outcomes Monitoring, Research and Prevention Branch Division of Birth Defects and Infant Disorders (DBDID)National Center on Birth Defects and Developmental Disorders Secretary's Advisory Committee on Infant Mortality Meeting January 25, 2021COVID-19 in Pregnancy Although rates of severe health outcomes are r elatively low, pregnant women with COVID- 19 are at increased risk of severe illness, which could result in: ICU admission Mechanical ventilation Death Pregnant women with COVID- 19 m ight have increased risk of adverse pregnancy outcomes, such as preterm birth. Hispanic and non- Hi spanic Black pregnant women appear to be disproportionately affected by COVID-19 infection during pregnancy. https://www.cdc.gov/coronavirus/2019- et al. Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory -Confi rmed SARS- CoV- 2 Infection by Pregnancy Status \u2014 United States, January 22 -October 3, 2020. MMWR http://dx.doi.org/10.15585/mmwr.mm6944e3COVID- 19 Pregnant women Limited data on the safety of COVID- 19 vaccines in pregnancy -Animal developmental and reproductive toxicity (DART) studies are ongoing -Studies in humans are ongoing and more planned mRNA vaccines and pregnancy -Not live vaccines -Degrade quickly by normal cellular processes and don't enter the nucleus of the cell If a woman is part of a group recommended to receive a COVID- 19 vaccine and is pregnant, she may choose to be vaccinated. A discussion with her healthcare provider can help her make an informed decision. https://www.cdc.gov/coronavirus/2019- ncov/need- extra -precautions/pregnancy -breastfeeding.htmlClinical Considerations: COVID-19 Vaccination in Pregnancy Considerations for vaccination: -level of COVID-19 community transmission (risk of acquisition) -her personal risk of contracting COVID-19 (by occupation or other activities) -the risks of COVID - 19 to her and potential risks to the fetus -the efficacy of the vaccine -the known side effects of the vaccine -the lack of data about the vaccine during pregnancy Pregnant women who experience fever following vaccination should be counseled to t ake acetaminophen as fever has been associated with adverse pregnancy outcomes Routine testing for pregnancy prior to receipt of a COVID- 19 v accine is not recommended. 4Breastfeeding/Lactating women There are no data on the safety of COVID- 19 vaccines in lactating women or the effects of mRNA vaccines on the breastfed infant or milk production/excretion mRNA vaccines are not thought to be a risk to the breastfeeding infant If a lactating woman is part of a recommended to receive a COVID- 19 vaccine, she may choose to be vaccinated V-safe & Pregnancy Smartphone -based tool that uses text messaging and web surveys to provide personalized health check- ins after receiving a COVID- 19 vaccination Additional follow- up with patients who received the vaccine during pregnancy or within 30 days of becoming pregnant One call each trimester, after delivery, and after the infant is 3 months old. Medical record request after delivery and after the infant is 3 months old. Goal: Better understand COVID- 19 vaccine effects and potential impact on pregnancy https://www.cdc.gov/coronavirus/2019 -ncov/vaccines/safety/vsafe.htmlFor more information, contact CDC 1-800-CDC- INFO (232- 4636) TTY: 1 -888-232-6348 www.cdc.gov The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. "}